However, 2 other GLP-1 agonist trials did not show a reduction in cardiovascular events: the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) [73], which randomized T2DM patients post-MI to lixisenatide or placebo, and the recently published Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial that failed to demonstrate a cardiovascular benefit of weekly injections of exenatide [74]. Here, GLP1R is linked to type 2 diabetes mellitus.